Sleep Apnea and Longevity: The Health Risks, Diagnosis and What Treatment Does
Obstructive sleep apnea affects an estimated 936 million adults aged 30 to 69 worldwide and is undiagnosed in the majority. It produces intermittent hypoxia dozens to hundreds of times per night, severely fragments sleep architecture, and drives chronic sympathetic nervous system activation, oxidative stress, and systemic inflammation. The longevity consequences - cardiovascular disease, cognitive decline, metabolic syndrome, and all-cause mortality - are substantial; treatment reliably improves sleepiness and quality of life, while its effect on heart attacks and strokes is less certain.
- Obstructive sleep apnea (OSA) is characterized by repetitive partial or complete collapse of the upper airway during sleep, producing episodes of hypoxia, hypercapnia, and sleep fragmentation that can occur 5 to 100+ times per hour. The resulting intermittent hypoxia pattern - unlike sustained hypoxia - is particularly damaging because the reoxygenation after each apnea generates a burst of reactive oxygen species.
- OSA is dramatically underdiagnosed: population studies estimate that 80 to 90 percent of moderate-to-severe OSA cases are undiagnosed. The classic presentation (obese, snoring male) represents only a subset - OSA affects women, lean individuals, and people without loud snoring in significant numbers. The STOP-BANG questionnaire is the most validated screening tool for clinical use.
- Untreated moderate-to-severe OSA is linked to higher blood pressure, atrial fibrillation, heart disease and stroke. CPAP lowers blood pressure, but in the large SAVE trial it did not prevent cardiovascular events in people who already had heart or brain vascular disease.
- OSA is linked to cognitive problems: it fragments sleep and causes repeated drops in brain oxygen, and imaging studies associate it with changes in the hippocampus and white matter. Whether treating it prevents dementia is not yet known.
- CPAP (continuous positive airway pressure) is the gold standard treatment and effectively eliminates apnea events in adherent users. Alternative treatments include mandibular advancement devices (effective in mild-to-moderate OSA), positional therapy (for position-dependent OSA), weight loss (reduces OSA severity substantially in obese individuals), and hypoglossal nerve stimulation (surgical option for CPAP-intolerant patients with appropriate anatomy).
The global prevalence of obstructive sleep apnea has reached epidemic proportions: estimates from the 2019 Benjafield et al. analysis in Lancet Respiratory Medicine put the number of adults aged 30 to 69 with OSA at about 936 million, with moderate-to-severe OSA in about 425 million. Most are undiagnosed, and many people who are diagnosed struggle to use treatment consistently.1
The Physiology of Obstructive Sleep Apnea
During normal sleep, the muscles of the upper airway (pharyngeal dilators) maintain airway patency against the negative pressure generated by breathing effort. In OSA, these muscles are insufficient to maintain airway patency - due to anatomical factors (reduced airway size, tongue and soft tissue volume, mandibular position), neuromuscular factors (impaired pharyngeal motor tone during sleep), and physiological factors (elevated loop gain - the instability of the ventilatory control system). When the airway collapses, airflow is reduced (hypopnea) or eliminated (apnea) for 10 to 90 seconds, until the resulting hypoxia and hypercapnia trigger an arousal response that restores muscle tone and reopens the airway.2
Laboratory studies suggest that the reoxygenation after each apnea, not just the low oxygen itself, drives much of the oxidative stress. Each reoxygenation event generates a burst of ROS via xanthine oxidase and NADPH oxidase activation - a pattern of intermittent hypoxia-reoxygenation that appears more harmful in experiments than steady low oxygen. In a person with severe OSA (AHI 60+ events per hour), this hypoxia-reoxygenation pattern occurs 60 to 100 times per night, every night, for years or decades.
Cardiovascular Consequences
The cardiovascular consequences of OSA are mediated through three primary mechanisms: oxidative stress and endothelial dysfunction from intermittent hypoxia-reoxygenation; chronic sympathetic nervous system activation from repeated arousals (which maintains elevated blood pressure 24 hours per day rather than the normal overnight blood pressure dip); and systemic inflammation from hypoxia-induced HIF-1 alpha activation and NF-kB-mediated cytokine production.3
The clinical consequences: OSA is common in people with high blood pressure, especially drug-resistant hypertension, and is linked to coronary disease, heart failure, atrial fibrillation and stroke. In a long-term cohort of men, untreated severe OSA was linked to about 2.9 times the odds of fatal cardiovascular events.7 Treating OSA with CPAP lowers blood pressure and can reduce atrial fibrillation recurrence, but in the SAVE trial of 2,717 adults with moderate-to-severe OSA and existing cardiovascular disease, CPAP did not prevent cardiovascular events, partly because many participants used it only a few hours a night.6
Brain and Cognitive Consequences
OSA’s effects on the brain are an active research area. Proposed mechanisms include fragmented deep sleep (which may reduce overnight brain waste clearance, based largely on animal work), repeated drops in brain oxygen, and impaired memory consolidation.4
Imaging studies associate moderate-to-severe untreated OSA with changes in the hippocampus, higher amyloid on PET scans in some studies, and white matter changes consistent with small-vessel disease, sometimes in people without memory complaints. Whether these changes lead to dementia, and whether treatment prevents them, is still being studied.
Diagnosis: Who Should Be Tested
The STOP-BANG questionnaire is a widely used OSA screening tool: Snoring (loud), Tired (daytime sleepiness), Observed apnea, blood Pressure (hypertension), BMI greater than 35, Age greater than 50, Neck circumference greater than 40 cm, and Gender (male). A score of 3 or more indicates high pretest probability and warrants sleep testing. However, OSA is common in people who do not fit the classic profile, and a lower threshold for testing is appropriate in any adult with unexplained hypertension, cognitive complaints, atrial fibrillation, or treatment-resistant depression.5
Home sleep testing (Level 2 or Level 3 devices) is now FDA-cleared and appropriate for diagnosing uncomplicated OSA in adults without significant comorbidities. In-laboratory polysomnography remains the gold standard for complex cases. The apnea-hypopnea index (AHI) from testing classifies severity: mild (5-14), moderate (15-29), severe (30+). Treatment is generally recommended for AHI of 15 or above, or for any severity with cardiovascular comorbidities or significant daytime sleepiness.
Put this research into practice: What Should I Test Next?
References
- 1Benjafield AV, et al. "Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis." Lancet Respir Med. 2019;7(8):687-698. PubMed · DOI
- 2Eckert DJ, Malhotra A. "Pathophysiology of adult obstructive sleep apnea." Proc Am Thorac Soc. 2008;5(2):144-53. PubMed · DOI
- 3Drager LF, et al. "Obstructive sleep apnea: an emerging risk factor for atherosclerosis." Chest. 2011;140(2):534-542. PubMed · DOI
- 4Andrade AG, et al. "The Relationship between Obstructive Sleep Apnea and Alzheimer's Disease." J Alzheimers Dis. 2018;64(s1):S255-S270. PubMed · DOI
- 5Chung F, et al. "STOP-Bang Questionnaire: A Practical Approach to Screen for Obstructive Sleep Apnea." Chest. 2016;149(3):631-8. PubMed · DOI
- 6McEvoy RD, et al. "CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea." N Engl J Med. 2016;375(10):919-31. PubMed · DOI
- 7Marin JM, et al. "Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study." Lancet. 2005;365(9464):1046-53. PubMed · DOI
